DSM Biologics to Acquire Rhobust Technology from Danish Firm

DSM Biologics says it has reached an agreement with biotech company Upfront Chromatography (Copenhagen, Denmark) for the acquisition of the assets and associated business of Rhobust technology for pharmaceutical and other applications. Financial details of the deal were not disclosed. DSM Biologics will gain all rights for the commercialization of Rhobust technology in various fields including the pharmaceutical industry, through the acquisition. “The acquisition of the Rhobust technology is an important addition to the portfolio of DSM Biologics,”...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers